Welcome to our dedicated page for Inhibikase Therapeutics SEC filings (Ticker: IKT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Inhibikase Therapeutics, Inc. filings document the disclosure record for a Nasdaq-listed clinical-stage pharmaceutical company developing IKT-001 for pulmonary arterial hypertension. Form 8-K reports cover operating and financial results, Regulation FD materials, clinical and regulatory updates for IMPROVE-PAH, and exhibits furnished with company press releases and corporate presentations.
Proxy and annual-meeting filings address board elections, auditor ratification, equity incentive plan amendments, executive compensation and shareholder voting results. Other disclosures describe the company's common stock, Nasdaq listing, inducement equity awards, material agreements, and capital-structure matters involving common stock and warrant securities.
ADAR1 Capital Management files an amendment reporting beneficial ownership stakes in Inhibikase Therapeutics. ADAR1 Capital Management is shown with 13,860,028 shares representing 9.9% of the issuer's common stock. The filing ties these figures to March 31, 2026 and to an outstanding share base of 132,032,636 shares reported in the issuer's Form 10-Q for the quarter ended March 31, 2026.
The cover pages list related parties: ADAR1 Capital Management GP, LLC with 11,832,998 shares (8.5%) and Daniel Schneeberger with 13,860,028 shares (9.9%). The reported holdings include common stock held by funds and shares underlying milestone warrants as described in the footnotes; the filing states ADAR1 acts in management/sub-advisory roles and may be deemed to indirectly beneficially own the referenced positions.
Inhibikase Therapeutics ownership update: Trails Edge Biotechnology Master Fund reports beneficial ownership of 8,057,345 shares of Inhibikase Therapeutics common stock, representing 6.1% of the outstanding shares as of the Event Date March 31, 2026. The filing states the 8,057,345 shares are held directly by Trails Edge Biotechnology and that Trails Edge Capital and Ortav Yehudai may be deemed to beneficially own the same shares due to management and voting discretion. The ownership percentage is calculated using 132,032,636 shares reported as issued and outstanding in the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2025.
Inhibikase Therapeutics ownership update: Commodore Capital LP, Commodore Capital Master LP and affiliated managers report beneficial ownership of 14,054,940 shares of common stock as of March 31, 2026. This amount is composed of 5,397,488 shares of common stock plus warrants to purchase 5,290,799 Tranche 1 and 3,366,653 Tranche 2 warrants. The filers state a 9.9% beneficial ownership limitation applies. The ownership percentage is calculated using 132,032,636 shares outstanding as of March 31, 2026 from the issuer's Form 10-Q.
INHIBIKASE THERAPEUTICS, INC. ownership disclosure: Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund report shared beneficial ownership equal to 8.9% of Common Stock.
The filing states 12,635,875 shares of shared voting and dispositive power and references 132,032,636 shares outstanding as of May 1, 2026, assuming exercise of Warrants for 10,320,875 shares subject to a 9.99% ownership limitation.
Inhibikase Therapeutics reported a larger quarterly loss as it advances its lead PAH drug IKT-001 into late-stage development. For the three months ended March 31, 2026, the company posted a net loss of $16.4 million, or $0.10 per share, compared with a $13.7 million loss a year earlier. Research and development expenses were $10.8 million, essentially flat year over year after excluding a prior one-time IPR&D charge, while selling, general and administrative costs rose to $7.4 million, driven mainly by higher stock-based compensation.
Other income increased to $1.5 million on interest from cash and marketable securities. Inhibikase ended the quarter with $170.4 million in cash, cash equivalents and marketable securities and an accumulated deficit of about $159.1 million, and believes this cash is sufficient to fund normal operations for at least 12 months. Operationally, the pivotal global IMPROVE-PAH Phase 3 study is enrolling patients, the first patient was enrolled in April 2026, and the company has secured approval to initiate the trial in 16 countries while pursuing approvals in more than 25. Inhibikase also submitted an Orphan Drug Designation application to the FDA for IKT-001 in PAH.
Inhibikase Therapeutics reported first quarter 2026 results and progress on its Pulmonary Arterial Hypertension program. The company enrolled the first patient in its registrational IMPROVE-PAH Phase 3 study and has obtained regulatory approvals in 16 countries, helped by the EMA’s new FAST-EU initiative.
As of March 31, 2026, cash, cash equivalents and marketable securities were $170.4 million. Net loss was $16.4 million, or $0.10 per share, compared with a net loss of $13.7 million, or $0.15 per share, a year earlier. Research and development expenses were $10.8 million, while selling, general and administrative costs were $7.4 million, both up versus the prior-year quarter.
Inhibikase Therapeutics, Inc. is soliciting proxies for its 2026 virtual annual meeting on June 26, 2026. Stockholders will elect two Class III directors, ratify CohnReznick LLP as auditor, and vote on several governance and compensation matters.
Key items include amending the certificate of incorporation to add Delaware-permitted liability protection for certain officers and expanding the 2020 Equity Incentive Plan by 3,000,000 shares of common stock. Stockholders will also cast advisory votes on executive pay and on whether future pay votes occur every one, two or three years, with the board recommending an annual vote. Common stock outstanding was 132,032,636 shares as of April 27, 2026.
Inhibikase Therapeutics, Inc. is soliciting proxies for its virtual 2026 Annual Meeting on to elect two Class III directors, ratify CohnReznick as auditor, approve an officer exculpation amendment to its charter, and approve a 3,000,000‑share increase to its 2020 Equity Incentive Plan. The Board recommends voting FOR each proposal and for an advisory "one year" frequency on executive compensation votes. Record holders as of April 27, 2026 may vote online using a 12‑digit control number; proxy materials and the 2025 Form 10‑K are available at www.proxydocs.com/IKT.
Inhibikase Therapeutics filed an 8-K to share news that the first patient has been enrolled in its pivotal global Phase 3 IMPROVE-PAH study of IKT-001 for Pulmonary Arterial Hypertension (PAH). This marks a key step in moving the program into late-stage testing.
IKT-001 is a novel oral prodrug of imatinib mesylate, designed to lessen gastrointestinal side effects associated with imatinib. The IMPROVE-PAH trial uses a two-part adaptive Phase 3 design with a 12-week dose‑titration phase to help patients reach the highest tolerable dose.
Part A will enroll approximately 140 patients and measure change in pulmonary vascular resistance at Week 24. Part B will follow seamlessly, enrolling about 346 patients and focusing on change in 6-minute walk distance at Week 24. The study may include up to roughly 180 sites worldwide and allows for sample size re-estimation for Part B based on Part A findings. Inhibikase describes PAH as a progressive, life‑threatening disease affecting about 50,000 Americans and views this single pivotal Phase 3 trial as central to advancing IKT-001 toward potential regulatory review.